This message was sent to ##Email##
|
|
|
|
|
| |
CNN
In a new effort to tackle the deadly opioid addiction crisis in the U.S., pharmacy giant CVS announced recently it will limit opioid prescriptions to seven days for certain conditions. This restriction will apply to patients who are new to pain therapy.
READ MORE
Pharmacy Practice News
19 patients with primary biliary cholangitis (PBC) have died after taking obeticholic acid (Ocaliva, Intercept Pharmaceuticals), prompting the FDA to issue a warning about improper dosing of the medication, which the agency has identified as a potential cause in a majority of the deaths.
READ MORE
AzPA Immunization Delivery Training Program
Sept. 30-Oct. 1 — Glendale, Arizona
Oct. 21 — Phoenix, Arizona
To register, click on the date of the program
(APhA) Pharmacy-Based Cardiovascular Disease Risk Management
October 28, 2017 – Phoenix, AZ
Click here to register.
AzPA
The AzPA CE Committee is calling for presenters to submit their suggested presentations for our Fall Conference, Southwestern Clinical Pharmacy Seminar, the Annual Convention, Virtual Webinars, and CE Journal home-study articles.
For additional information and to download the Call for Speakers Application, click here.
AbbVie
Join Dennis Song, RD, RPh, CHC, as he presents A Dialogue on Hypothyroidism on October 5th. This quality educational dinner speaker program will be held at Roy’s in Chandler. For more information or to register for this program, please click here.
CNBC
Amazon is ramping up conversations with a group of drug middlemen known as pharmacy benefits managers or PBMs, according to analysts from Leerink Partners. PBMs are a critical part of the drug supply chain, as they negotiate prices with drug manufacturers on one end, and manage pharmacy benefits for insurers on the other.
READ MORE
Reuters
Intellipharmaceutics International Inc said recently the U.S. Food and Drug Administration (FDA) declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug’s abuse-deterrence capabilities.
READ MORE
Los Angeles Times
Seeking to prevent superbug outbreaks, federal health officials said they have approved the first gastrointestinal medical scope with a disposable cap for use in the U.S.
The Food and Drug Administration said that the design of the new duodenoscope by Japanese device maker Pentax should make it easier to remove dangerous bacteria that can become trapped inside these reusable instruments.
READ MORE
By David M. Heckman
 Our politicians are in the process of wasting tax dollars on ineffective and misguided efforts to resolve the opioid crisis. These funds will likely be spent by many of the people responsible for the crisis. The problem is that politicians focus on demonizing medications instead of addressing human behaviors, which are the real underlying cause. Suing drug manufacturers over presumed "failure to warn" will not result in any benefit to persons harmed by this crisis.
READ MORE
HealthPayer Intelligence
61 percent of pharmaceutical companies are not yet participating in value-based contracts due largely to the belief that current policies make it too difficult to negotiate with payers and see a return on investment, according to a PricewaterhouseCoopers report.
READ MORE
|
Missed last week's issue? See which articles your colleagues read most.
|
|
Don't be left behind. Click here to see what else you missed.
|
The Citizens' Voice
With many drug prices rising, consumers often pull out coupons or discount cards from drugmakers to save money when they buy medications at pharmacies. But some insurers are limiting how those discounts may be applied amid concerns they’re driving up health care costs for everyone.
READ MORE
USA Today
Puerto Rico's pharmaceutical industry came to a halt after Hurricane Maria devastated the island. Drug companies ranging from Eli Lilly to AstraZeneca rushed to assess damage and braced for the possibility of months of downtime.
READ MORE
Pharmacy Practice News
When added to standard therapies, dupilumab (Dupixent, Sanofi/Regeneron) reduced severe asthma exacerbations and improved lung function, according to a phase 3 study in a broad population of patients with uncontrolled, persistent asthma.
READ MORE
|
|
|
|
50 Minthorn Blvd.Suite 800, Thornhill, Ontario L3T 7X8
|
